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Abstract
Purpose of Review This review provides an overview of well-established and newly developed cartilage repair techniques for
cartilage defects in the patellofemoral joint (PFJ). An algorithm will be presented for approaching cartilage defects considering
the distinct anatomy of both the patellar and trochlear articular surfaces.
Recent Findings Recent studies on cartilage repair in the PFJ have demonstrated improved outcomes in an attempt to delay or
obviate the need for arthroplasty, and improve symptoms in young patients. While autologous chondrocyte implantation shows
good and excellent outcomes for chondral lesions, osteochondral defects are adequately addressed with osteochondral allograft
transplantation. In case of patellar malalignment, concomitant tibial tubercle osteotomy can significantly improve outcomes.
Particulated cartilage and bone marrow aspirate concentrate are potential new alternative treatments for cartilage repair, currently
in early clinical studies.
Summary Due to the frequency of concomitant anatomic abnormalities in the PFJ, a thorough clinical examination combined
with careful indication for each procedure in each individual patient combined with meticulous surgical technique is central to
achieve satisfying outcomes. Additional comparative studies of cartilage repair procedures, as well as investigation of newer
techniques, are needed.
Keywords Patellofemoral joint . Chondral lesion . Cartilage repair . Osteochondral allograft . Autologous chondrocyte
implantation . Particulated allograft
Introduction
The management of articular cartilage defects remains a chal-
lenging clinical problem for orthopedic surgeons. Articular
cartilage is a highly organized tissue with complex biome-
chanical properties and substantial durability. However, it
has poor intrinsic capacity for healing, and defects can lead
to considerable functional impairment, subsequent joint de-
generation, and development of osteoarthritis (OA) [1]. In
the United States (US) alone, OA is a condition that affects
up to 27 million people with an estimated economic cost of 89
billion US dollars annually [2].
The patellofemoral joint (PFJ) is frequently involved in
symptomatic cartilage disease of the knee [3]. A recent
meta-analysis revealed that, based on magnetic resonance im-
aging (MRI), up to 52% of patients with knee pain or symp-
tomatic OA of the knee are diagnosed with cartilage lesions in
the PFJ [4•]. Moreover, patellofemoral OA has been associat-
ed with symptoms of pain, stiffness, and functional limitations
[5]. The pathomechanism of patellofemoral OA is multifacto-
rial, including chronic repetitive microtrauma due to subopti-
mal extensor mechanism alignment, and acute macrotrauma,
most commonly patellar dislocations, which are associated
with cartilage defects in up to 95% of patients [6, 7••].
Chondral lesions on the patellar and trochlear articular
surfaces are particularly challenging to manage due to the
complex biomechanical environment and substantial load
transmission through the PFJ during weight-bearing activity
[8].
First-line conservative treatment of cartilage lesions, in gen-
eral, aims to relieve inflammation and controlling pain to regain
functional capacity. This can be achieved with nonsteroidal
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anti-inflammatory medications, intra-articular corticosteroid in-
jections, and hyaluronic acid viscosupplementation [8]. In ad-
dition to muscle strengthening to improve absorption of phys-
iological loads across the knee, weight loss and activity modi-
fication to avoid aggravating pain and functional limitation
may improve symptoms [9, 10]. Conservative treatment of pa-
tients with anterior knee pain should be attempted for at least
3 months before considering surgical intervention, as most pa-
tients will experience pain relief with physical therapy and can
therefore avoid surgical treatment [11, 12].
Surgical treatment options for focal cartilage lesions in
the knee include debridement/chondroplasty, bone marrow
stimulation, autologous chondrocyte implantation (ACI),
osteochondral autograft transfer (OAT), osteochondral allo-
graft transplantation (OCA), and newer techniques such as
particulated cartilage procedures (autograft and juvenile al-
lograft). Choosing a surgical treatment is based on morpho-
logical factors of the chondral lesion such as the location
within the knee joint (femoral condyles vs. patellofemoral),
location on the involved articular surface (i.e., inferior vs.
superior patellar pole), size, depth (involvement of the
subchondral bone), containment (contained vs. not
contained), as well as on patient characteristics like age,
body mass index (BMI), limb and extensor mechanism
alignment, and activity level.
Also, adequate treatment of concomitant pathologies is cru-
cial to the success of any cartilage repair in the knee. This
review will concentrate solely on cartilage lesions in the
PFJ, and therefore, tibial tubercle osteotomy (TTO) will be
discussed briefly.
First described for the treatment of patellar instability [13],
anteromedialization of the tibial tubercle has also been found
to unload the PFJ [14]. The procedure can improve
patellofemoral contact mechanics in patients with
patellofemoral malalignment by transferring contact forces
from distal to proximal and from lateral to medial on the
patellar articular surface [15•]. Hence, this procedure is espe-
cially valuable in patients with chondral lesions on the infe-
rior pole or lateral facet of the patella [12]. Due to its signif-
icant positive impact on clinical outcomes, TTO is frequently
performed concomitantly with patellofemoral cartilage repair
in patients with PF maltracking [7••, 16–19, 20••].
This article provides a review of the current state of
cartilage repair in the PFJ, focusing on well-established,
as well as emerging techniques meeting the distinct require-
ments of cartilage repair in the PFJ. Moreover, we will
provide an algorithm to adequately address patellofemoral
cartilage defects.
Chondroplasty
Chondroplasty, also referred to as cartilage debridement, is
one of the most performed procedures involving cartilage
[24]. The goal of chondroplasty is to transform an irregular
and unstable cartilage lesion into a more regular and stable
construct. It is typically indicated for partial or full-thickness
chondral lesions smaller than 1–2 cm2 but can also be per-
formed in larger lesions preparing the site for a subsequent
cartilage repair procedure such as ACI [25]. In the senior
author’s practice, most patients undergo chondroplasty during
the cartilage biopsy in the first stage of an elective ACI for the
PFJ and/or tibiofemoral joint (TF).
It appears of importance to create a regular lesion with
stable vertical walls. However, the negative effects on carti-
lage viability beyond the area of resection remain controver-
sial, and therefore, overly aggressive debridement should be
avoided [26–30]. Surgeon’s attention is critical to neither
transform a contained into an uncontained lesion nor to need-
lessly expose the subchondral bone [31].
Reports of clinical outcomes for chondroplasty in the PFJ
remain limited. Anderson et al. [32•] retrospectively studied
86 patients who were submitted to isolated chondroplasty for
chondral lesions in the knee with a mean size of 3.3 cm2 and
ICRS grades 2–4. The majority of these patients had lesions in
the PFJ (58.5%). The authors found that patients with lower
preoperative scores gained more benefit from chondroplasty,
but no correlation between anatomic location and amount of
improvement could be observed. Federico and Ryder [33]
reviewed the records of 36 patients who underwent arthro-
scopic debridement for chondral lesions of the patella. While
57.9% of patients with traumatic chondromalacia had good or
excellent results, only 41.1% with atraumatic chondromalacia
showed good or excellent results after chondroplasty.
Bone Marrow Stimulation
Bone marrow stimulation refers to any technique that pro-
motes the migration of pluripotent mesenchymal stem
cells from the subchondral bone to the chondral defect
surface, thereby promoting fibrocartilage repair. The most
popular techniques are the Pridie drilling technique, using
K wires, and the microfracture technique described and
popularized by Steadman and colleagues, which uses
angulated awls [34, 35].
While full thickness and contained chondral lesions of up
to 4 cm2 are an acceptable indication for performing
microfracture in the TF, a lower threshold (2 cm2) should be
considered for the PFJ. This is due to the distinctive biome-
chanics and higher sheer stresses in this joint, which would
affect durability of the formed fibrocartilage. Furthermore,
superior outcomes were observed in patients younger than
40 years, BMI under 30 kg/m2, and duration of symptoms less
than 12 months. Importantly, microfracture should be avoided
in uncontained chondral lesions [36].
Surgical principles remain the same regardless of the cho-
sen technique and are paramount for success. It is essential to
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perform a thorough debridement all the way down to the
subchondral bone, including the layer of calcified cartilage,
with stable, verticals walls to create adequate containment.
Next, the perforations must be perpendicular to the bony sur-
face, at least 3 mm deep, and spaced 3 to 4 mm apart from
each other (Fig. 1). This will cause bleeding, clot formation,
and the migration of the pluripotent mesenchymal stem cells
into the cartilage defect. As a result, fibrocartilage with type I
collagen will be produced that has, however, inferior biome-
chanical properties compared to the type II collagen typical for
native hyaline cartilage. While lesions in the trochlea can be
easily addressed by arthroscopy, patellar defects are more
challenging to approach. A small arthrotomy may be neces-
sary for lesion visualization and proper instrument angulation.
Additionally, counter pressure on the anterior aspect of the
patella may be needed during bone marrow stimulation due
to greater mobility and harder bone of the patella.
Kreuz et al. [37] evaluated 85 patients who underwent
microfracture and compared the outcomes of different ana-
tomic locations within the knee. The authors concluded that
microfracture results in short-term improvement followed by a
sharp decline in outcomes after 2 years of follow-up.
Interestingly, the functional outcomes in patients with
patellofemoral chondral lesions were worse regardless of fol-
low-up. Mithoefer et al. [36] showed that the failure rate was
up to 6% in the first 2 years, with an increase of up to 31%
after 5 years of follow-up. Minas et al. [38] demonstrated a 3-
fold increase in failure rate of ACI after a previous marrow
stimulant procedure compared to primary ACI (26 vs. 8%),
showing that microfracture can negatively affect the outcomes
of subsequent procedures. Consequently, the senior author
performs a bone marrow procedure only in small chondral
lesions (< 2 cm2) of the PFJ (and mostly limited to the troch-
lea), thus maximizing the likelihood of a successful outcome
without the need for subsequent procedures.
Recently, bone marrow aspirate concentrate (BMAC) has
emerged as an alternative treatment option. Though its appli-
cation is still under investigation, BMAC has the advantage of
not damaging the local subchondral bone while allowing
higher numbers of mesenchymal stem cells to be brought into
the defect. The bone marrow clot is implanted into the defect
under a membrane cover to stabilize the reparative tissue.
[46•]. BMAC can also serve as a biological augmentation
for other procedures such as OAT and OCA (Fig. 2).
Hopefully, our understanding of the clinical benefits of
BMAC will increase with future results of ongoing studies
[46•, 47].
Autologous Chondrocyte Implantation
ACI is one of the senior author’s most performed procedures
for chondral lesions in the PFJ. It allows the treatment of larger
defects and matching of the complex contour of the patellar
and trochlear articular surfaces. With more than 25 years of
experience, ACI technology has evolved but the two-stage
technique principles remain the same [48]. The first stage
involves the arthroscopic harvesting of 100–300 mg of full-
thickness articular cartilage from non-weight-bearing areas of
Fig. 1 Arthroscopic image of a small, well-contained chondral lesion
treated with microfracturing. Note that the holes are 3–4 mm apart from
each other to prevent tunnel collapse
Fig. 2 Intraoperative image of an autologous chondrocyte implantation
(ACI) to the central trochlear. The collagen membrane is secured with 6-0
absorbable sutures and watertight sealed with fibrin glue
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the femoral condyle, or the superior and lateral margin of the
intercondylar notch. In vitro, the cartilage matrix is processed
and the chondrocytes are cultured for at least 2 weeks.
During the second stage, the chondral defect is debrided
and the cultured chondrocytes are implanted. The debride-
ment must be performed carefully, avoiding damage to the
subchondral plate and creating stable vertical walls. Then,
the chondrocyte-seeded collagen membrane is placed in
the defect and secured with either fibrin glue alone in case
of excellent containment or fixed to the surrounding carti-
lage with 6-0 absorbable sutures. (Fig. 2).
The original technique, also referred to as first-generation
ACI, utilized a periosteal patch that was harvested from the
patient’s proximal tibia [49]. As a result of overgrowth issues
and inferior outcomes, periosteal patches were progressively
replaced by collagen membranes—bilayered synthetic biode-
gradable scaffolds for ingrowth of chondrocytes—which
formed the second-generation ACI [50, 51]. Aside from the
containment function, scaffolds have the potential of in vivo
chondroinduction and chondroconduction [52]. In the current
third-generation ACI, also known as matrix-induced autolo-
gous chondrocyte implantation (MACI), the chondrocytes are,
again, cultured in vitro but replicated inside a three-
dimensional scaffold membrane [53••]. While comprising
the same scaffold associated potentials, the application of
MACI also simplifies the surgery by omitting both the chon-
drocyte injection underneath a membrane and the watertight
sealing to ensure chondrocyte containment within the lesion.
While studies have demonstrated reduced rates of re-operation
inmembraneACI comparedwith periosteal ACI, further com-
parative studies are needed to show superiority among these
techniques [54, 55•, 56].
ACI is indicated in full-thickness chondral lesions larger
than 3–4 cm2 and can be performed in the TF and PFJ.
Preoperative assessment of the subchondral bone on MR-
imaging is of critical importance. Patients with subchondral
plate alterations may require concomitant bone grafting
(“sandwich” technique), or osteochondral transplantation
in order to address the subchondral bone. ACI should be
avoided in patients with previous bone marrow stimulation
procedures and significant subchondral changes such as
cystic degeneration and extensive subchondral edema [38,
50].
As in other cartilage repair techniques, it is important to
achieve good containment of the chondral defect prior to
ACI. In patellar lesions, however, this can be more challenging
to accomplish due to the unique anatomy of its articular surface.
To resolve this issue, ACI can be performed in conjunction with
OAT to ensure proper containment [57]. Contraindications for
ACI include inflammatory arthritis, obesity, and smoking.
Although considered a contraindication for primary treatment,
bipolar lesions can be addressed with ACI as a salvage proce-
dure exhibiting encouraging results [58••, 59••, 60].
In contrast to other cartilage procedures, ACI for the PFJ
has been extensively studied in the literature. Initial reports of
the outcome after ACI in the PFJ were disappointing [49].
Improved ACI techniques and the treatment of concomitant
patellofemoral malalignment, along with better understanding
of the patellofemoral biomechanics, led to enhanced outcomes
in recent years [61•, 62–64, 65•, 66]. Gomoll et al. [6] evalu-
ated 110 patients with patellofemoral ACI in a multi-center
study across the US. A total of 84% of patients had good or
excellent results after a minimum of 4-year follow-up. Similar
results were obtained by von Keudell et al. [21••], showing
that 83% of patients had good or excellent functional out-
comes after ACI to isolated chondral lesions of the patella
with a failure rate of 10% after 15 years of follow-up. As
previously mentioned, lateral facet or inferior pole patellar
lesions should be addressed with ACI in combination with
an anteromedializing TTO to achieve improved outcomes
[17, 19, 67•].
ACI sandwich technique refers to the use of two mem-
branes with impaction grafting of the subchondral bone defi-
cit. It has shown excellent results in the treatment of
osteochondral defects on the femoral condyles [68, 69], but
further studies must investigate its eligibility as primary option
in the PFJ.
Lately, arthroscopic techniques for ACI have emerged
showing encouraging results. Ebert et al. [70•] reported 90%
of good or excellent outcomes after arthroscopic MACI with
5 years of follow-up. In contrast, Biant et al. [71•] demonstrat-
ed a 16-fold increase in cellular viability when ACI was per-
formed using a mini-arthrotomy compared with an arthro-
scopic approach, suggesting that the arthroscopic procedure
has the potential to negatively affect chondrocyte viability.
In a recent systematic review, Andriolo et al. [22••] evalu-
ated 58 studies and found an overall failure rate of 14.9% for
ACI across the knee joint, most of them occurring in the first
5 years without differences between ACI and MACI tech-
niques. The authors criticized the heterogeneous description
of failure among all studies and underlined the importance of a
coherent definition of failure. Another systematic review
looked at MACI outcomes in a 5-year follow-up period and
found a significantly higher failure rate in the TF compared to
the PFJ (12.4 vs. 4.7%) [23•] (Table 1).
ACI remains a costly treatment option for patients with
chondral defects in the knee. Though, the procedure cost-
effectiveness seems to be inside the range of other cartilage
procedures, considering the substantial delay of other more
aggressive and expensive procedures such as partial of total
knee arthroplasty [72, 73•, 74•].
Osteochondral Autograft Transfer (OAT)
This technique describes the harvesting of 10–15 mm deep
osteochondral cylinders from healthy, non-weight-bearing
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areas of the knee, typically the medial or lateral margins of the
trochlea, posterior femoral condyles, or intercondylar notch,
and transferring them to the defect site of the ipsilateral knee
(Fig. 3). While OAT has the advantage of transferring hyaline
cartilage in a one-stage procedure with good bony integration
and no risk of immunologic complications, donor site morbid-
ity remains a concern in OAT procedures. This limits the in-
dication for OAT to only small cartilage lesions up to 2–3 cm2
in size [75]. In a biomechanical study, Garretson et al. [76]
found that the medial trochlea and distal lateral trochlea had
the lowest contact loads and hence could provide desirable
cylinder grafts for the PFJ.
Precise graft fitting and creating of a smooth articular sur-
face in the PFJ are essential to achieving satisfactory results in
patients after OAT. In fact, graft prominence of more than
1 mm has shown to be associated with less favorable out-
comes, and patients frequently describe persistent catching
sensations months after the surgery [77, 78, 79•].
This is particularly challenging in the PFJ as a result of two
issues: The unique anatomy of the patellar and trochlear sur-
faces complicates forming a smooth articular surface; every
donor graft will have a thinner cartilage layer than the sur-
rounding patella and thus, results in local cartilage bone inter-
face mismatch [80].
Some authors reported up to 92% good to excellent re-
sults in patients with chondral lesions on the femoral con-
dyle, while lesions in the PFJ showed 79% good to excel-
lent results [81]. Especially patellar lesions have been re-
ported to be associated with less favorable results with up
to 100% failure rate after 1 year follow-up, which is
thought to be due to the previously described anatomic
characteristics of the PFJ [39•, 82]. Yet, other authors be-
lieve that patellofemoral malalignment plays an important
role in the outcome of OAT to the patella. They found
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Fig. 3 Intraoperative image of two osteochondral autograft plugs
transferred to both the patella and trochlea. Note that the lateral margin of
the trochlea served as donor site to harvest both osteochondral cylinders
192 Curr Rev Musculoskelet Med (2018) 11:188–200
significant improvement in clinical outcomes and 100%
graft integration after 12 months follow-up in patients
with small (< 2.5 cm2) full-thickness chondral lesion of
the patella without malalignment of the PFJ [40••].
Recently, Yabumoto et al. [79•] stated that if high con-
gruity is achieved through meticulous implantation of
donor grafts perpendicular to the articular surface, fa-
vorable results can be obtained for chondral lesions in
the PFJ.
Osteochondral Allograft Transplantation
Osteochondral Allograft Transplantation (OCA) is possi-
bly the most challenging cartilage procedure in the PFJ. As
described for OAT, precise fitting of the harvested plug and
creating a smooth surface is key to the success of the pro-
cedure. The same principle applies to OCA, but the process
of donor graft matching is complicated by the anatomic
complexity and variability of the PFJ. Proper assessment
of preoperative imaging studies for PFJ allograft matching is
yet to be determined [83, 84].
With stricter guidelines imposed by the FDA for allograft
tissue acquisition and storage, the risk of disease transmission
decreased and OCA has become increasingly popular as a
primary or salvage procedure [24, 85]. Fresh osteochondral
allografts are harvested within 24 h of donor’s death and are
preserved at a temperature of 4 °C [86]. Current recommen-
dations advise a storage time of up to 28 days, but ideal shelf
life remains controversial [87, 88•]. This storage technique has
shown adequate chondrocyte viability and is routinely used
for OCA [86, 89].
OCA is performed via an arthrotomy with a size and
side-matched donor plug to precisely press fit into the
prepared defect (Fig. 4). Despite the fact that allograft
immunogenicity is related to graft volume, no differences
were observed in survival rates for different graft sizes
[90••]. Nevertheless, reducing the thickness of the graft’s
subchondral bone is thought to reduce the potential risk of
immunoreaction [83]. Additionally, pulse lavage washing
of the graft is performed in an attempt to decrease marrow
contents [91, 92].
OCA is indicated as a primary procedure in large full-
thickness cartilage lesions, typically greater than 2 cm2,
with abnormal subchondral bone [83], but increasingly al-
so for the primary treatment of pure chondral lesions.
Besides the prospect of addressing uncontained defects,
OCA has the advantage of being a single-stage procedure
while avoiding potential donor site morbidity compared
with OAT. Moreover, it is a potential option for the treat-
ment of bipolar lesions, but with inferior results when
compared to outcomes in single lesions, similar to other
cartilage repair options such as ACI [43•]. It can also serve
as a salvage procedure in patients after failed cartilage
repair and in patients with post-traumatic osteochondral
defects after knee fractures that are too young for
arthroplasty [86, 89, 93, 94]. Relative contraindications
for OCA include smoking and obesity as they have shown
to negatively affect clinical outcomes [87, 95•]. Extensor
mechanism malalignment, ligamentous instability, or other
intra-articular pathologies should be simultaneously ad-
dressed if needed to achieve improved outcomes.
There is a paucity in the current literature of randomized
controlled trials for OCA, and only few studies have re-
ported outcomes for patellofemoral OCA, albeit with good
results [96]. Cameron et al. [42••] evaluated 29 knees with
trochlear OCA with a mean follow-up of 7 years. Graft
survivorship was 100% at 5 years and 91.7% at 10 years
with improvement of all functional outcomes and an over-
all satisfaction rate of 89%. Gracitelli et al. [41••] studied
28 knees with OCA for isolated patellar cartilage lesions
with 9.7 years of mean follow-up time. Patellar allograft
survivorship was 78.1% at 5 and 10 years, decreasing to
55.8% at 15 years with an overall satisfaction rate of 89%.
The obtained results are in conformity with outcomes re-
ported by previous studies [97, 98].
OCA failure rate has been shown to be higher in the PFJ
than in the TF. In a systematic review, Assenmacher et al.
[99•] reported failure rates of 50 and 24% for OCA after a
mean follow-up of 12.3 years in the PFJ and TF, respectively.
Also, the reoperation rate was higher in the PFJ group when
compared to the TF group (83 vs. 34%).
In terms of indication for OCA, the senior author distin-
guishes between chondral lesions affecting the patellar or
trochlear articular surface. In the patella, OCA is typically
performed after previously failed repair of large chondral le-
sions over 2 cm2 to provide pain relief and delay arthroplasty
in young patients. In the trochlea, OCA can either be a primary
Fig. 4 Intraoperative image of a flush seated osteochondral allograft to
the trochlea. Marking of the 12 o’clock ensures correct insertion and thus
perfect fitting of the osteochondral allograft plug
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treatment option for osteochondral lesions over 2 cm2 or serve
as a salvage procedure after failed cartilage repair.
Additionally, BMAC augmentation is frequently performed
to enhance graft integration [46•, 95•] (Fig. 5).
Particulated Cartilage Procedures
This relatively new treatment option includes particulated ar-
ticular cartilage using autograft or juvenile allografts
(DeNovo, Zimmer, Warsaw, IN) from donors aged 0–13 years
[100•]. Analogous to OAT, articular cartilage is harvested
from non-weight-bearing areas of the ipsilateral knee for the
autograft procedure. Once the cartilage is mechanically
minced, it is re-implanted into the chondral lesion and sealed
with fibrin glue. A preclinical study demonstrated that
particulated autograft loaded on composite scaffold produced
hyaline-like cartilage [101]; one clinical study showed encour-
aging results for addressing lesions on the femoral condyle
and trochlea [102].
Particulated juvenile allograft is mechanically minced
into 1–2 mm pieces and stored in vials containing enough
material to cover lesions up to 2.5 cm2. Similar to autolo-
gous particulated cartilage, the chondral lesion is filled with
particulated allograft up to 1 mm below the surrounding
shoulders of healthy cartilage and finally secured with fi-
brin glue (Fig. 6). Indications include focal chondral lesions
between 1 and 6 cm2 and ICRS grade 3 or higher in patients
preferably younger than 55 years and a BMI less than
35 kg/m2 [100•].
There is a limited body of literature reporting clinical out-
comes for particulated juvenile allograft transplantation.
However, several authors demonstrated favorable results in
patients with focal chondral lesions on the patella and trochlea
[44•, 45•, 103], with good to excellent defect fill in short and
mid-term results [45•, 104•]. Particulated juvenile articular
cartilage has also been found to produce a mixture of hyaline
and fibrocartilage with a dominance of type II collagen after
2 years follow-up [45•] (Table 2).
Postoperative Rehabilitation
Postoperative protocols differ between institutions and remain
a topic of great discussion. Although a standard postoperative
rehabilitation protocol for PFJ cartilage repair is presented,
each case should be carefully evaluated and the protocol ad-
justed as needed.
Generally, we recommend cryotherapy, elevation, and a
brace for pain control during the immediate postoperative pe-
riod. After 2 or 3 days, weight-bearing as tolerated is allowed
in a locked brace, and continuous progressive passive motion
is started. Range of motion (ROM) is encouraged to prevent
arthrofibrosis with no restrictions. Therefore, with assist of
continuous passive motion (CPM), we advance ROM gain
to 90° of flexion as fast as patients tolerate it, at least 5° a
day. In case of concomitant TTO, partial weight-bearing is
recommended for 4–6 weeks. Return to sports is not advisable
until 6 to 12 months after surgery based on senior author’s
experience. There are no differences on the protocol for patel-
lar or trochlear lesions.
Fig. 5 BMAC augmentation of an osteochondral allograft. Bone marrow
is extracted from the lateral femoral condyle or tibial plateau
Fig. 6 Intraoperative image of particulated juvenile osteochondral
allograft to a chondral lesion on the patella
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Conclusion
Cartilage repair in the PFJ has demonstrated increasingly
good outcomes in patients with patellofemoral cartilage
defects after conservative treatment has failed. The algo-
rithm presented in Fig. 7 intends to serve as a simplified
guide for the surgical management of chondral lesions in
the PFJ. It is of utmost importance to discuss with the
patient current functional limitations in sports and activi-
ties of daily living, to elucidate the patient’s goals and
expectations, and to go over the rehabilitation and recov-
ery time. Unrealistic expectations are common and will
lead to disappointment. Careful evaluation of the knee
and lower extremity through physical examination and
imaging studies is crucial. This will allow planning a
comprehensive treatment approach for the cartilage repair
procedure, as well as any additional pathology that needs
to be addressed in a staged or concomitant fashion.
The anatomic complexity and variability of the PFJ is a
great challenge to all cartilage procedures. The increased
attention to, and correction of, pathologic co-morbidities
such as patellar instability and maltracking has led to a sub-
stantial improvement in results. While early outcomes of
cartilage repair in the PFJ were disappointing, current com-
prehensive treatment approaches demonstrate outcomes that
are comparable or only slightly inferior to cartilage repair in
the TF.
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